United States · FDA National Drug Code directory
Repaglinide
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 65862-672_54d938ac-ebf2-49d0-8056-f65d8aadfb98
- Product NDC
- 65862-672
- Form
- TABLET
- Composition / generic term
- Repaglinide
- Labeler
- Aurobindo Pharma Limited
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20140122
- Source listing expiry
- 20261231
Source-listed ingredients
- REPAGLINIDE — 2 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 100 TABLET in 1 BOTTLE (65862-672-01) · 65862-672-01
- 500 TABLET in 1 BOTTLE (65862-672-05) · 65862-672-05
- 1000 TABLET in 1 BOTTLE (65862-672-99) · 65862-672-99
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →